drugset / Trial / NCT00546585

Safety, Reactogenicity, and Immunogenicity of Inactivated Influenza A/H7/N7 Vaccine in Healthy Adults

NCT00546585

RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to evaluate the safety, any adverse events or side effects, and the body's immune response to an experimental flu vaccine \[Inactivated Influenza A/H7N7 Vaccine\] being given in increasing doses. Researchers will try to find the smallest dose of flu vaccine needed to cause antibody responses against the flu virus in both single and repeat doses. The study will enroll 125 healthy adults ranging in age from 18 to 40 years old. Subjects will be given 2 doses of the vaccine 28 days apart. Study procedures will include obtaining a medical history, physical exam, blood sample collections, and use of patient memory aids. The volunteers will be in the study for about 7 months.

Timeline

Start
2008-03
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Influenza A/H5N1 Vaccine Vaccine 7.5 ug Intramuscular
Subject Influenza A/H5N1 Vaccine Vaccine 15 ug Intramuscular
Subject Influenza A/H5N1 Vaccine Vaccine 45 ug Intramuscular
Subject Influenza A/H5N1 Vaccine Vaccine 90 ug Intramuscular

Indications